# Study to Assess Safety of an Inactivated H5N1 Influenza Vaccine Administered in GelVac Nasal Powder to Healthy Young Adults

> **NCT01258062** · PHASE1 · COMPLETED · sponsor: **Alachua Government Services, Inc.** · enrollment: 7 (actual)

## Conditions studied

- Phase 1 Safety Study of GelVac Nasal Powder H5N1 Influenza Vaccine

## Interventions

- **DRUG:** GelVac™ nasal powder H5N1 influenza vaccine.
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01258062
- **Lead sponsor:** Alachua Government Services, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2017-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01258062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01258062, "Study to Assess Safety of an Inactivated H5N1 Influenza Vaccine Administered in GelVac Nasal Powder to Healthy Young Adults". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01258062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*